Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
RESEARCH TOOLSreports
Holding TERN?
Track your performance easily
TERN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.32 - $11.40
Previous Close$6.24
Volume702.99K
Average Volume (3M)2.08M
Market Cap
$530.02M
Enterprise Value$158.55M
Total Cash (Recent Filing)$372.78M
Total Debt (Recent Filing)$1.30M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Apr 01, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding84,938,855
10 Day Avg. Volume1,450,673
30 Day Avg. Volume2,075,199
Standard Deviation0.29
R-Squared0.00296
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.30
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.51
Forecast
1Y Price Target
$18.92Price Target Upside203.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Terns Pharmaceuticals News
PremiumCompany Announcements
Terns Pharmaceuticals Reports Promising Results in CML Trial
PremiumCompany Announcements
Terns Pharmaceuticals Appoints Heather Turner to Board
PremiumCompany Announcements
Terns Pharmaceuticals Reports Q3 Progress and Financials
Bulls Say, Bears Say
Bulls Say
Clinical ExpansionThe strategic focus on expanding clinical programs is highlighted by plans to initiate a Phase 2 trial of TERN-601 for obesity, which suggests potential for growth.
Financial PerformanceA cash balance of $372.8M is expected to provide runway into 2028, ensuring financial stability for ongoing and future trials.
Product DifferentiationTERN-701 is potentially differentiated by tolerability, specifically the lack of a food effect and need for fasting around dosing, suggesting a competitive advantage.
Bears Say
Adverse EventsTERN-601 treatment at the 740 mg dose resulted in the highest incidence of Grade 2 (moderate) adverse events, which were mostly gastrointestinal in nature.
Clinical Trial DataPatient efficacy data at the interim will contain less than six months of follow-up data, providing only early directional signals of efficacy.
Financial PerformanceTERN reported 3Q24 net loss of $21.9M.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TERN FAQ
What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was $4.32 and its highest was $11.40 in the past 12 months.
What is Terns Pharmaceuticals’s market cap?
Currently, no data Available
When is Terns Pharmaceuticals’s upcoming earnings report date?
Terns Pharmaceuticals’s upcoming earnings report date is Apr 01, 2025 which is in 103 days.
How were Terns Pharmaceuticals’s earnings last quarter?
Terns Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.04.
Is Terns Pharmaceuticals overvalued?
According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued.
Does Terns Pharmaceuticals pay dividends?
Terns Pharmaceuticals does not currently pay dividends.
What is Terns Pharmaceuticals’s EPS estimate?
Terns Pharmaceuticals’s EPS estimate is -$0.31.
How many shares outstanding does Terns Pharmaceuticals have?
Terns Pharmaceuticals has 84,938,860 shares outstanding.
What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
Terns Pharmaceuticals reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went down -5.439%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals?
Among the largest hedge funds holding Terns Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Terns Pharmaceuticals’s shares valued at 17M.
---
Terns Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.92 (203.21% Upside)
$18.92 (203.21% Upside)
Blogger Sentiment
Bullish
TERN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 317.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
50.00%
12-Months-Change
Fundamentals
Return on Equity
-28.28%
Trailing 12-Months
Asset Growth
39.22%
Trailing 12-Months
Company Description
Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
---
TERN Stock 12 Month Forecast
Average Price Target
$18.92
▲(203.21% Upside)
Technical Analysis
Best Analysts Covering TERN
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+8.09%
initiated a buy rating last month
Copying Etzer Darout's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +8.09% per trade.
---